Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
XXX - Bifidobacterium breve + Bifidobacterium longum + Fructooligosaccharides (FOS) + Lacticaseibacillus casei + Lacticaseibacillus rhamnosus + Lactobacillus acidophilus + Lactobacillus delbrueckii bulgaricus + Streptococcus thermophilus & Type 2 Diabetes (T2D) is a randomized double-blind placebo-controlled clinical trial to study Bifidobacterium breve + Bifidobacterium longum + Fructooligosaccharides (FOS) + Lacticaseibacillus casei + Lacticaseibacillus rhamnosus + Lactobacillus acidophilus + Lactobacillus delbrueckii bulgaricus + Streptococcus thermophilus or placebo in 54 randomized patients with Type 2 Diabetes (T2D) (1)